Paradigm Biocapital Advisors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001855655

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 30 positions · Total reported value $3.92B · Top-10 concentration 70.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.3% · 7 new · 6 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2025 13F filing, Paradigm Biocapital Advisors LP disclosed 30 equity positions with a combined reported value of $3.92B. The filing implies a focused portfolio: its ten largest positions account for 70.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were NUVL ($530.05M), RVMD ($529.23M), ACLX ($373.21M). By sector, the heaviest allocations are Health Care 60.6%, Industrials 1.7%. Versus the prior quarter, allocation shifted toward Health Care (+2.5pp), Industrials (+0.8pp) and away from Other (-3.2pp).

Versus the prior quarter, Paradigm Biocapital Advisors LP opened 7 new positions, trimmed 6 and fully exited 6, a turnover rate of 54.3% of positions. The portfolio's overlap with the prior quarter was 52% of names.

The largest new positions opened in Q4 2025 were ORKA ($51.84M), LXEO ($47.30M), TERN ($32.74M).

Of the 6 positions fully exited versus the prior quarter, the largest were JANX ($71.37M), ALKS ($51.58M), LENZ ($50.00M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • ORKA ORUKA THERAPEUTICS INC · $51.84M
  • LXEO LEXEO THERAPEUTICS INC · $47.30M
  • TERN TERNS PHARMACEUTICALS INC · $32.74M
  • VOR VOR BIOPHARMA INC · $22.89M
  • ASMB ASSEMBLY BIOSCIENCES INC · $22.63M
  • ORIC ORIC PHARMACEUTICALS INC · $19.64M
  • IVA INVENTIVA SA · $18.60M
  • KLRS KALARIS THERAPEUTICS INC · $5.91M

Fully Exited (vs previous quarter)

  • JANX JANUX THERAPEUTICS INC · prev qtr: $71.37M
  • ALKS ALKERMES PLC · prev qtr: $51.58M
  • LENZ LENZ THERAPEUTICS INC · prev qtr: $50.00M
  • PHVS PHARVARIS N V · prev qtr: $45.80M
  • COGT COGENT BIOSCIENCES INC · prev qtr: $45.33M
  • MRUS MERUS N V · prev qtr: $28.25M
  • TNGX TANGO THERAPEUTICS INC · prev qtr: $25.92M · history
  • AMLX AMYLYX PHARMACEUTICALS INC · prev qtr: $25.82M

Insider Transactions (Form 4)

Latest Paradigm Biocapital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Paradigm Biocapital Advisors LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 28 positions worth $5.34B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-120338 (status: Approved), registered 2021-02-23
  • Regulatory AUM (Form ADV): $4.47B as of 2026-08-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 28 positions · $5.34B reported value (Q2 2026)
  • Top 10 holdings = 75.2% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 22.3%
  • Average position size: $190.73M

Sector Tilt

  • Health Care 81.2%
  • Industrials 0.8%
  • (classified holdings cover 82% of value)

Quarterly Activity

  • Q2 2026: 7 new, 12 added, 7 reduced, 14 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 60.6%
Other 37.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 5.27M $530.05M 13.53%
13.53%
Hold
2 6.64M $529.23M 13.51%
13.51%
Add
3 5.72M $373.21M 9.53%
9.53%
Add
4 7.04M $216.83M 5.53%
5.53%
Add
5 2.56M $209.79M 5.36%
5.36%
Reduce
6 1.42M $191.15M 4.88%
4.88%
Reduce
7 7.54M $188.60M 4.81%
4.81%
Add
8 4.07M $187.70M 4.79%
4.79%
Add
9 1.50M $182.90M 4.67%
4.67%
Add
10 759.57K $167.78M 4.28%
4.28%
Reduce
11 6.54M $162.32M 4.14%
4.14%
Add
12 3.06M $134.89M 3.44%
3.44%
Add
13 4.47M $104.77M 2.67%
2.67%
Add
14 2.21M $102.91M 2.63%
2.63%
Reduce
15 1.12M $84.78M 2.16%
2.16%
Reduce
16 3.69M $67.44M 1.72%
1.72%
Add
17 14.16M $52.67M 1.34%
1.34%
Add
18 684.28K $52.34M 1.34%
1.34%
Hold
19 1.71M $51.84M 1.32%
1.32%
New
20 1.47M $48.07M 1.23%
1.23%
Hold
21 4.76M $47.30M 1.21%
1.21%
New
22 1.44M $44.91M 1.15%
1.15%
Reduce
23 2.94M $35.63M 0.91%
0.91%
Reduce
24 810.29K $32.74M 0.84%
0.84%
New
25 2.26M $28.32M 0.72%
0.72%
Add
26 1.75M $22.89M 0.58%
0.58%
New
27 665.25K $22.63M 0.58%
0.58%
New
28 2.40M $19.64M 0.50%
0.50%
New
29 4.00M $18.60M 0.47%
0.47%
New
30 700.00K $5.91M 0.15%
0.15%
New

FAQ

What did Paradigm Biocapital Advisors LP buy in 2025-Q4?

In its 2025-Q4 13F filing, Paradigm Biocapital Advisors LP reported 30 equity positions worth $3.92B in aggregate; its largest disclosed positions were NUVL ($530.05M), RVMD ($529.23M), ACLX ($373.21M).

How large is Paradigm Biocapital Advisors LP's portfolio?

Paradigm Biocapital Advisors LP reported $3.92B of long equity holdings across 30 positions as of 2025-Q4. Top-10 holdings account for 70.9% of reported value.

What is Paradigm Biocapital Advisors LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/paradigm-biocapital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →